These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Review of the performance of the 3T3 NRU in vitro phototoxicity assay in the pharmaceutical industry. Lynch AM; Wilcox P Exp Toxicol Pathol; 2011 Mar; 63(3):209-14. PubMed ID: 20060695 [TBL] [Abstract][Full Text] [Related]
24. Prediction of a new drug's potential to cause idiosyncratic reactions. Uetrecht J Curr Opin Drug Discov Devel; 2001 Jan; 4(1):55-9. PubMed ID: 11727323 [TBL] [Abstract][Full Text] [Related]
25. Fast method development and rapid analysis using a screening approach for enantiomeric separations in capillary electrophoresis. Jimidar MI; Van Ael W; Shah R; Redlich D; De Smet M J Capill Electrophor Microchip Technol; 2003; 8(5-6):101-10. PubMed ID: 15369174 [TBL] [Abstract][Full Text] [Related]
26. Post-column infusion study of the 'dosing vehicle effect' in the liquid chromatography/tandem mass spectrometric analysis of discovery pharmacokinetic samples. Shou WZ; Naidong W Rapid Commun Mass Spectrom; 2003; 17(6):589-97. PubMed ID: 12621622 [TBL] [Abstract][Full Text] [Related]
27. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Whitebread S; Hamon J; Bojanic D; Urban L Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262 [TBL] [Abstract][Full Text] [Related]
29. An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults. Santagostino A; Garbaccio G; Pistorio A; Bolis V; Camisasca G; Pagliaro P; Girotto M Haematologica; 1999 Jun; 84(6):499-504. PubMed ID: 10366792 [TBL] [Abstract][Full Text] [Related]
30. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Hondeghem LM Eur J Pharmacol; 2008 Apr; 584(1):1-9. PubMed ID: 18304526 [TBL] [Abstract][Full Text] [Related]
31. Prediction of genotoxicity of chemical compounds by statistical learning methods. Li H; Ung CY; Yap CW; Xue Y; Li ZR; Cao ZW; Chen YZ Chem Res Toxicol; 2005 Jun; 18(6):1071-80. PubMed ID: 15962942 [TBL] [Abstract][Full Text] [Related]
32. A simple strategy for mitigating the effect of data variability on the identification of active chemotypes from high-throughput screening data. Johnson SR; Padmanabha R; Vaccaro W; Hermsmeier M; Cacace A; Lawrence M; Dickey J; Esposito K; Pike K; Wong V; Poss M; Loughney D; Tebben A J Biomol Screen; 2007 Mar; 12(2):276-84. PubMed ID: 17272827 [TBL] [Abstract][Full Text] [Related]
34. Metabolites in safety testing. Robison TW; Jacobs A Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045 [TBL] [Abstract][Full Text] [Related]
35. The future of drug safety testing: expanding the view and narrowing the focus. Stevens JL; Baker TK Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337 [TBL] [Abstract][Full Text] [Related]
36. Strategies for dealing with reactive intermediates in drug discovery and development. Nassar AE; Lopez-Anaya A Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156 [TBL] [Abstract][Full Text] [Related]
37. The silent treatment. Smith C Nature; 2003 Mar; 422(6929):342. PubMed ID: 12646928 [No Abstract] [Full Text] [Related]
38. Correct assessment of new compounds using in vivo screening models can reduce false positives. Bueters TJ; Hoogstraate J; Visser SA Drug Discov Today; 2009 Jan; 14(1-2):89-94. PubMed ID: 18840543 [TBL] [Abstract][Full Text] [Related]
39. An optical method for continuous monitoring of the dissolution rate of pharmaceutical powders. Laitinen R; Lahtinen J; Silfsten P; Vartiainen E; Jarho P; Ketolainen J J Pharm Biomed Anal; 2010 Jun; 52(2):181-9. PubMed ID: 20116958 [TBL] [Abstract][Full Text] [Related]
40. [Biological trials of physiologically active compounds (the methodology). II]. Landau MA Fiziol Cheloveka; 2000; 26(3):126-30. PubMed ID: 10905044 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]